<DOC>
	<DOCNO>NCT00726804</DOCNO>
	<brief_summary>Spondylarthropathy ( SpA ) comprise group rheumatic disease mainly affect spine sacroiliac joint . In patient disease activity alternate , patient symptom free period . Tumor-Necrosis-Factor-alpha ( TNF-alpha ) antagonists significantly improve treatment option patient spondyloarthritis . TNF-alpha antagonist therapy costly , implies increase risk infection , include reactivation tuberculosis , risk long-term adverse event , cancer , fully clarify . It highly relevant explore extent anti-TNF-alpha therapy discontinue SpA patient without immediate relapse disease activity . Two study investigate discontinuation TNF-alpha antagonist ( infliximab etanercept ) ankylose spondylitis , report flare majority patient within 1-year follow-up period , long time relapse patient low disease activity . The effect adalimumab discontinuation never study , , furthermore , effect TNF-alpha-antagonist discontinuation never study patient early spondyloarthritis fulfil New York criterion .</brief_summary>
	<brief_title>Discontinuation TNF-alpha Inhibitors Patients With Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . At least 12 month treatment infliximab , etanercept adalimumab . 2 . Diagnosis spondylarthritis accord European Spondyloarthritis Study Group ( ESSG ) criterion modify New York Criteria 3 . No clinical active disease , define BASDAI score &lt; 4 . 4 . Among issue : Age &gt; 18 year ; write informed consent , adequate birth control ; contraindication antiTNFalphatherapy 1 . Treatment disease modify antirheumatic drug within 4 week screen 2 . Oral , intraarticular , intramuscular intravenous glucocorticoid within 4 week screen 3 . Pregnancy lactation 4 . HIV , hepatitis B C , tuberculosis , infection 5 . Malignancies 6 . Other serious concomitant disease ( uncontrolled/severe kidney , liver , haematological , gastrointestinal , endocrine , cardiovascular , pulmonary , neurological ore cerebral disease ( include demyelinate disease ) 7 . Contraindications antiTNFalphatherapy 8 . Contraindications MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>